277 related articles for article (PubMed ID: 26308156)
1. The role of aldo-keto reductase 1C3 (AKR1C3)-mediated prostaglandin D2 (PGD2) metabolism in keloids.
Mantel A; Newsome A; Thekkudan T; Frazier R; Katdare M
Exp Dermatol; 2016 Jan; 25(1):38-43. PubMed ID: 26308156
[TBL] [Abstract][Full Text] [Related]
2. Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism.
Mantel A; Carpenter-Mendini A; VanBuskirk J; Pentland AP
Exp Dermatol; 2014 Aug; 23(8):573-8. PubMed ID: 24917395
[TBL] [Abstract][Full Text] [Related]
3. AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells.
Wang S; Yang Q; Fung KM; Lin HK
Mol Cell Endocrinol; 2008 Jul; 289(1-2):60-6. PubMed ID: 18508192
[TBL] [Abstract][Full Text] [Related]
4. Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer.
Byrns MC; Duan L; Lee SH; Blair IA; Penning TM
J Steroid Biochem Mol Biol; 2010 Feb; 118(3):177-87. PubMed ID: 20036328
[TBL] [Abstract][Full Text] [Related]
5. The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs.
Desmond JC; Mountford JC; Drayson MT; Walker EA; Hewison M; Ride JP; Luong QT; Hayden RE; Vanin EF; Bunce CM
Cancer Res; 2003 Jan; 63(2):505-12. PubMed ID: 12543809
[TBL] [Abstract][Full Text] [Related]
6. Aldo-keto reductase 1C3 is expressed in differentiated human epidermis, affects keratinocyte differentiation, and is upregulated in atopic dermatitis.
Mantel A; Carpenter-Mendini AB; Vanbuskirk JB; De Benedetto A; Beck LA; Pentland AP
J Invest Dermatol; 2012 Apr; 132(4):1103-10. PubMed ID: 22170488
[TBL] [Abstract][Full Text] [Related]
7. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors.
Penning TM; Steckelbroeck S; Bauman DR; Miller MW; Jin Y; Peehl DM; Fung KM; Lin HK
Mol Cell Endocrinol; 2006 Mar; 248(1-2):182-91. PubMed ID: 16417966
[TBL] [Abstract][Full Text] [Related]
8. Involvement of an aldo-keto reductase (AKR1C3) in redox cycling of 9,10-phenanthrenequinone leading to apoptosis in human endothelial cells.
Matsunaga T; Arakaki M; Kamiya T; Endo S; El-Kabbani O; Hara A
Chem Biol Interact; 2009 Sep; 181(1):52-60. PubMed ID: 19442656
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells.
Doig CL; Battaglia S; Khanim FL; Bunce CM; Campbell MJ
J Steroid Biochem Mol Biol; 2016 Jan; 155(Pt A):47-55. PubMed ID: 26429394
[TBL] [Abstract][Full Text] [Related]
10. The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis.
Birtwistle J; Hayden RE; Khanim FL; Green RM; Pearce C; Davies NJ; Wake N; Schrewe H; Ride JP; Chipman JK; Bunce CM
Mutat Res; 2009 Mar; 662(1-2):67-74. PubMed ID: 19162045
[TBL] [Abstract][Full Text] [Related]
11. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
[TBL] [Abstract][Full Text] [Related]
12. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
Zhong T; Xu F; Xu J; Liu L; Chen Y
Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
[TBL] [Abstract][Full Text] [Related]
13. 15-Deoxy-Δ12,14-prostaglandin J2 induces PPARγ- and p53-independent apoptosis in rabbit synovial cells.
Sakaba Y; Awata H; Morisugi T; Kawakami T; Sakudo A; Tanaka Y
Prostaglandins Other Lipid Mediat; 2014 Jun; 109-111():1-13. PubMed ID: 24680891
[TBL] [Abstract][Full Text] [Related]
14. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
Guise CP; Abbattista MR; Singleton RS; Holford SD; Connolly J; Dachs GU; Fox SB; Pollock R; Harvey J; Guilford P; Doñate F; Wilson WR; Patterson AV
Cancer Res; 2010 Feb; 70(4):1573-84. PubMed ID: 20145130
[TBL] [Abstract][Full Text] [Related]
15. 15-Deoxy-Delta(12,14)-prostaglandin J2 induces IL-8 and GM-CSF in a human airway epithelial cell line (NCI-H292).
Chiba T; Ueki S; Ito W; Kato H; Takeda M; Kayaba H; Furue M; Chihara J
Int Arch Allergy Immunol; 2009; 149 Suppl 1():77-82. PubMed ID: 19494510
[TBL] [Abstract][Full Text] [Related]
16. Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.
Byrns MC; Penning TM
Chem Biol Interact; 2009 Mar; 178(1-3):221-7. PubMed ID: 19010312
[TBL] [Abstract][Full Text] [Related]
17. PTHrP stimulates prostate cancer cell growth and upregulates aldo-keto reductase 1C3.
Downs TM; Burton DW; Araiza FL; Hastings RH; Deftos LJ
Cancer Lett; 2011 Jul; 306(1):52-9. PubMed ID: 21444150
[TBL] [Abstract][Full Text] [Related]
18. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
Byrns MC; Steckelbroeck S; Penning TM
Biochem Pharmacol; 2008 Jan; 75(2):484-93. PubMed ID: 17950253
[TBL] [Abstract][Full Text] [Related]
19. Aldo-keto reductase 1C3 may be a new radioresistance marker in non-small-cell lung cancer.
Xie L; Yu J; Guo W; Wei L; Liu Y; Wang X; Song X
Cancer Gene Ther; 2013 Apr; 20(4):260-6. PubMed ID: 23519145
[TBL] [Abstract][Full Text] [Related]
20. Activation of the MAPK/Akt/Nrf2-Egr1/HO-1-GCLc axis protects MG-63 osteosarcoma cells against 15d-PGJ2-mediated cell death.
Koyani CN; Kitz K; Rossmann C; Bernhart E; Huber E; Trummer C; Windischhofer W; Sattler W; Malle E
Biochem Pharmacol; 2016 Mar; 104():29-41. PubMed ID: 26801686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]